Drug Information

Drug General Information
Drug ID
D08SSP
Former ID
DNCL002997
Drug Name
Lersivirine
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Phase 2 [523279]
Company
ViiV Healthcare
Structure
Download
2D MOL

3D MOL
Formula
C17H19N4O2+
Canonical SMILES
CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)[N+]#C)C#N
InChI
1S/C17H19N4O2/c1-4-15-17(16(5-2)21(20-15)6-7-22)23-14-9-12(11-18)8-13(10-14)19-3/h3,8-10,22H,4-7H2,1-2H3/q+1
InChIKey
FDKFFEDNWJEELJ-UHFFFAOYSA-N
PubChem Compound ID
71296127
PubChem Substance ID
162012056
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Inhibitor [531272]
References
Ref 523279ClinicalTrials.gov (NCT01254656) A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022. U.S. National Institutes of Health.
Ref 531272Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.